Trial Profile

Safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in patients with actinic keratoses

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ingenol disoxate (Primary) ; Ingenol mebutate
Indications Actinic keratosis
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors LEO Pharma

Most Recent Events

03 Nov 2015 New trial record
27 Oct 2015 Results published on-line British Journal of Dermatology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com